– UK, London – Avacta Group Plc (LON: AVCT), the developer of Affimer biotherapeutics and reagents, today announced the appointment of Paul Fry as Non-Executive Director with effect from 3d February 2020. Paul will be appointed Chair of the Audit Committee.
“I am delighted to welcome Paul to the Board of Avacta. Paul has significant financial and commercial experience in the pharmaceutical and biotech sector and his appointment reflects our commitment to attracting the best talent to the Company. We look forward to working with him as Avacta develops into a clinical-stage biotechnology company.” said Dr Eliot Forster, Chairman of Avacta Group.
About Paul Fry
Paul has extensive financial experience across a number of industries including biotech, pharmaceutical and telecommunications. He is currently CFO of Vectura Group plc, an industry-leading inhaled drug delivery specialist listed on the FTSE Main Market.
Prior to his current position, he was CFO of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor technology. Paul has also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GlaxoSmithKline, where he held a number of senior roles including Head of Global Finance Services and Chief Financial Officer for GSK’s Italian pharmaceutical business.
Paul Fry commented: “I am excited by the opportunity to work with Avacta in their mission to develop novel cancer immunotherapies and to commercialise the Affimer technology in other markets. I look forward to helping support the evolution of the Company and realising value for both patients and shareholders.”
About Avacta Group Plc
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer biotherapeutics and pre|CISION tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.
The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.
Avacta’s pre|CISION platform, activates chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thus improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.
By combining these two platforms the Company is building a wholly-owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic in the middle of 2020.
Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a collaboration with LG Chem to develop treatments for autoimmune and inflammatory diseases worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and a joint venture in South Korea with Daewoong Pharmaceuticals to develop the next generation of stem cell therapies that incorporate Affimer immuno-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.
The Avacta diagnostics business unit works with partners worldwide to develop Affimers for evaluation by those third parties with the objective of establishing royalty-bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.
For more information: https://avacta.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
